James Blankenship

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

Jeffrey S. Berger, Matthew T. Roe, C. Michael Gibson et al. · American Heart Journal · 2009 · 100 citations

Medicine, Cardiology, Pharmacotherapy +17

Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group.

Thomas C. Wall, Robert M. Califf, James Blankenship et al. · Circulation · 1994 · 93 citations · Full text

Pharmacy, Cardiology, Pharmacotherapy +14

A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.

Cindy L. Grines, Steven E. Nissen, David C. Booth et al. · Circulation · 1991 · 85 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

Muthiah Vaduganathan, Robert A. Harrington, Gregg W. Stone et al. · Journal of the American College of Cardiology · 2017 · 57 citations

Medicine, Cardiology, Pharmacology +14

Routine functional testing after percutaneous coronary intervention

Mark J. Eisenberg, Brooke E. Wilson, Claude Lauzon et al. · Acta Cardiologica · 2007 · 24 citations

Medicine, Cardiology, Nuclear Medicine +17